Sign in

CIK 0001501989

  • Accelerated filer

CytomX Therapeutics, Inc.

Sign in to watch
Ticker
CTMX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
273521219
Phone
+1 650-515-3185
Business address
151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Grant or award SVP, Chief Scientific Officer acquired 60,000 shares (grant or award)
  2. 3 Insider Initial Statement of Ownership
  3. 4 Open-market sale SVP, Finance and Accounting sold 516 shares at $1.98 ($1,021)
  4. 4 Open-market sale CEO sold 7,121 shares at $1.88 ($13,391)
  5. 4 Open-market sale Chief Financial Officer sold 1,748 shares at $1.98 ($3,459)
  6. 4 Open-market sale General Counsel sold 2,037 shares at $1.98 ($4,031)
  7. 4 Open-market sale Chief Financial Officer sold 1,477 shares at $1.98 ($2,923)
  8. 4 Open-market sale EVP, Chief Development Officer sold 4,257 shares at $1.98 ($8,425)
  9. 4 Grant or award CEO acquired 105,000 shares (grant or award)
  10. 4 Grant or award Chief Business Officer acquired 40,000 shares (grant or award)
  11. 4 Grant or award General Counsel acquired 25,000 shares (grant or award)
  12. 4 Grant or award SVP, Finance and Accounting acquired 25,000 shares (grant or award)
  13. 4 Derivatives Options or other derivatives
  14. 4 Derivatives Options or other derivatives
  15. 4 Derivatives Options or other derivatives
  16. 4 Derivatives Options or other derivatives
  17. 4 Open-market sale EVP, Chief Development Officer sold 7,463 shares at $1.42 ($10,612)
  18. 4 Open-market sale Chief Business Officer sold 4,206 shares at $1.42 ($5,982)
  19. 4 Open-market sale President and CEO sold 14,911 shares at $1.42 ($21,206)
  20. 4 Open-market sale General Counsel sold 5,602 shares at $1.42 ($7,968)

Page 6 of 20 · 400 filings